Antimicrobial susceptibility and molecular characteristics of Mycoplasma bovis isolated from cases of bovine respiratory disease in Australian feedlot cattle.

Hasoon, MF; Jarocki, VM; Mohammed, MH; Djordjevic, SP; Yip, HYE; Carr, M; Khabiri, A; Azari, AA; Amanollahi, R; Jozani, RJ; Carracher, B; Mollinger, J; Deutscher, AT; Hemmatzadeh, F; Trott, DJ

Antimicrobial susceptibility and molecular characteristics of Mycoplasma bovis isolated from cases of bovine respiratory disease in Australian feedlot cattle.

Hasoon, MF Jarocki, VM Mohammed, MH Djordjevic, SP Yip, HYE Carr, M Khabiri, A Azari, AA Amanollahi, R Jozani, RJ Carracher, B Mollinger, J Deutscher, AT Hemmatzadeh, F Trott, DJ

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Vet Microbiol, 2023, 283, pp. 109779
Issue Date:: 2023-08

Closed Access

	Filename	Description	Size
	1-s2.0-S0378113523001311-main.pdf	Accepted version	1.15 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Hasoon, MF
dc.contributor.author	Jarocki, VM
dc.contributor.author	Mohammed, MH
dc.contributor.author	Djordjevic, SP
dc.contributor.author	Yip, HYE
dc.contributor.author	Carr, M
dc.contributor.author	Khabiri, A
dc.contributor.author	Azari, AA
dc.contributor.author	Amanollahi, R
dc.contributor.author	Jozani, RJ
dc.contributor.author	Carracher, B
dc.contributor.author	Mollinger, J
dc.contributor.author	Deutscher, AT
dc.contributor.author	Hemmatzadeh, F
dc.contributor.author	Trott, DJ
dc.date.accessioned	2023-09-29T04:36:55Z
dc.date.available	2023-05-19
dc.date.available	2023-09-29T04:36:55Z
dc.date.issued	2023-08
dc.identifier.citation	Vet Microbiol, 2023, 283, pp. 109779
dc.identifier.issn	0378-1135
dc.identifier.issn	1873-2542
dc.identifier.uri	http://hdl.handle.net/10453/172381
dc.description.abstract	To date, antimicrobial susceptibility has not been reported for Australian Mycoplasma bovis isolates. This study determined minimal inhibitory concentrations (MICs) for 12 different antimicrobials against Australian M. bovis isolates and used whole genome sequencing to screen those showing high macrolide MICs for point mutations in target genes. Most lung tissue/swab samples from bovine respiratory disease cases (61/76, 80.3%) tested positive for M. bovis. A set of 50 representative isolates (50/61, 82.0%) that showed adequate growth, was used for MIC testing. Uniformly, low MIC values were confirmed for enrofloxacin (≤ 4 μg/mL), florfenicol (≤ 8 μg/mL), gamithromycin (≤ 2 μg/mL), spectinomycin (≤ 4 μg/mL), tetracycline (≤ 8 μg/mL), tiamulin (≤ 4 μg/mL), and tulathromycin (≤ 0.5 μg/mL). A small proportion (10%) of isolates exhibited high MICs (≥ 32 μg/mL) for tildipirosin, tilmicosin, tylosin, and lincomycin, which were above the epidemiological cut-off values for each antimicrobial (≥ 4 μg/mL). These isolates, originating from three Australian states, underwent whole genome sequencing/multilocus sequencing typing and were compared with the reference strain PG45 to investigate mutations that might be linked with the high macrolide/lincosamide MICs. All five belonged to ST52 and two macrolide associated mutations were identified within the 23 S rRNA gene (A2058G in two sequenced isolates and G748A in all sequenced isolates). Four additional 23 S rRNA gene mutations did not appear to be linked to macrolide resistance. Whilst the majority of Australian M. bovis isolates appear susceptible to the tested antimicrobials, emerging macrolide resistance was detected in three Australian states and requires continued monitoring.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Vet Microbiol
dc.relation.isbasedon	10.1016/j.vetmic.2023.109779
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0605 Microbiology, 0707 Veterinary Sciences
dc.subject.classification	Veterinary Sciences
dc.subject.classification	3009 Veterinary sciences
dc.subject.classification	3107 Microbiology
dc.subject.mesh	Animals
dc.subject.mesh	Cattle
dc.subject.mesh	Anti-Bacterial Agents
dc.subject.mesh	Anti-Infective Agents
dc.subject.mesh	Australia
dc.subject.mesh	Cattle Diseases
dc.subject.mesh	Drug Resistance, Bacterial
dc.subject.mesh	Macrolides
dc.subject.mesh	Microbial Sensitivity Tests
dc.subject.mesh	Mycoplasma bovis
dc.subject.mesh	Mycoplasma Infections
dc.subject.mesh	Animals
dc.subject.mesh	Cattle
dc.subject.mesh	Mycoplasma bovis
dc.subject.mesh	Mycoplasma Infections
dc.subject.mesh	Cattle Diseases
dc.subject.mesh	Macrolides
dc.subject.mesh	Anti-Infective Agents
dc.subject.mesh	Anti-Bacterial Agents
dc.subject.mesh	Microbial Sensitivity Tests
dc.subject.mesh	Drug Resistance, Bacterial
dc.subject.mesh	Australia
dc.subject.mesh	Animals
dc.subject.mesh	Cattle
dc.subject.mesh	Anti-Bacterial Agents
dc.subject.mesh	Anti-Infective Agents
dc.subject.mesh	Australia
dc.subject.mesh	Cattle Diseases
dc.subject.mesh	Drug Resistance, Bacterial
dc.subject.mesh	Macrolides
dc.subject.mesh	Microbial Sensitivity Tests
dc.subject.mesh	Mycoplasma bovis
dc.subject.mesh	Mycoplasma Infections
dc.title	Antimicrobial susceptibility and molecular characteristics of Mycoplasma bovis isolated from cases of bovine respiratory disease in Australian feedlot cattle.
dc.type	Journal Article
utslib.citation.volume	283
utslib.location.activity	Netherlands
utslib.for	0605 Microbiology
utslib.for	0707 Veterinary Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - AIMI - Australian Institute for Microbiology & Infection
utslib.copyright.status	closed_access	*
dc.date.updated	2023-09-29T04:36:53Z
pubs.publication-status	Published
pubs.volume	283

Abstract:

To date, antimicrobial susceptibility has not been reported for Australian Mycoplasma bovis isolates. This study determined minimal inhibitory concentrations (MICs) for 12 different antimicrobials against Australian M. bovis isolates and used whole genome sequencing to screen those showing high macrolide MICs for point mutations in target genes. Most lung tissue/swab samples from bovine respiratory disease cases (61/76, 80.3%) tested positive for M. bovis. A set of 50 representative isolates (50/61, 82.0%) that showed adequate growth, was used for MIC testing. Uniformly, low MIC values were confirmed for enrofloxacin (≤ 4 μg/mL), florfenicol (≤ 8 μg/mL), gamithromycin (≤ 2 μg/mL), spectinomycin (≤ 4 μg/mL), tetracycline (≤ 8 μg/mL), tiamulin (≤ 4 μg/mL), and tulathromycin (≤ 0.5 μg/mL). A small proportion (10%) of isolates exhibited high MICs (≥ 32 μg/mL) for tildipirosin, tilmicosin, tylosin, and lincomycin, which were above the epidemiological cut-off values for each antimicrobial (≥ 4 μg/mL). These isolates, originating from three Australian states, underwent whole genome sequencing/multilocus sequencing typing and were compared with the reference strain PG45 to investigate mutations that might be linked with the high macrolide/lincosamide MICs. All five belonged to ST52 and two macrolide associated mutations were identified within the 23 S rRNA gene (A2058G in two sequenced isolates and G748A in all sequenced isolates). Four additional 23 S rRNA gene mutations did not appear to be linked to macrolide resistance. Whilst the majority of Australian M. bovis isolates appear susceptible to the tested antimicrobials, emerging macrolide resistance was detected in three Australian states and requires continued monitoring.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/172381